drugset
Drugs / VB10.NEO
last change Oct 2024 re-read 3 minutes ago

VB10.NEO

Vaccine

Investigated by
Nykode Therapeutics ASA · Vaccibody AS · Genentech, Inc. · Nektar Therapeutics

Trials 2

today NCT05018273 · Ph 1 NCT03548467 · Ph 1/2
201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05018273 Dec 2021 → Oct 2024 — Nykode Therapeutics ASA Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT03548467 Apr 2018 → Jan 2023 — Nykode Therapeutics ASA Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2020-08-12 Nektar Therapeutics Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients with Squamous Cell Carcinoma of the Head and Neck nektar.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as VB10.NEO ClinicalTrials.gov intervention name — accepted as the source's own label NCT03548467 ↗
1

NCT05018273 ↗
Modality Vaccine “VB10.NEO is a vaccine” NCT03548467 ↗
Route Intramuscular “VB10.NEO 3 mg will be administered by IM injection” NCT05018273 ↗